Salute e Benessere

TriNetX's Founding CEO Announces Plans to Step Down

"It has been an honor to build TriNetX and be part of such an outstanding team. I want to thank TriNetX's employees, customers, and shareholders for the support they have shown me. With the talent and passion of our people I am immensely confident in TriNetX's continued success," said Lachman. "Together, we have built the largest global platform for clinical research, with data from over 25 countries and tens of millions of queries a month. Our solutions are moving clinical…
PR Newswire
09/01/2025

FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025

The waiver applies to the Company's LPT-CBD drug product, developed for subcutaneous injection to manage chronic pain in dogs. With growing interest in CBD products among pet owners seeking safe and effective ways to support their pets' health, Innocan's LPT-CBD aims to deliver precise and sustained CBD release from a single injection. This innovation offers a safe and convenient dosing solution for managing chronic pain in dogs, providing benefits for pets of all ages and sizes. The waiver...
PR Newswire
09/01/2025

Transforming Healthcare: AI in Diagnostics Market to See 27.6% CAGR Growth

This report provides an overview of the global market for AI in clinical and molecular diagnostics, covering market size, growth trends, and key applications such as medical imaging, genomics, and lab testing. It focuses on the factors driving AI adoption, challenges, and opportunities, along with profiles of leading companies and regional insights. Emerging trends in personalized medicine and telehealth are also discussed, making this report a valuable resource for healthcare providers, tech…
PR Newswire
09/01/2025

Kindeva Drug Delivery and Emervax Partner To Bring Game Changing Vaccine…

Kindeva's microneedle array patch provides accurate and reliable intradermal delivery of Emervax's emxRNATM vaccines. A typical emxRNATM dose range aligns with the payload capacity of microneedle technology and improves the stability profile of emxRNATM vaccines, potentially reducing the need for cold chain storage. It is also a minimally invasive way of administering vaccines, helping to remove barriers to vaccination takeup due to its ease of use, potential for at-home dosing and pain free…
PR Newswire
09/01/2025

Global Biotechnology Market Outlook 2025: Driving Growth at 13.0% CAGR |…

Browse in-depth TOC on "Global Biotechnology Industry Outlook"10 - Tables20 - Figures70 - Pages Browse in-depth TOC on "Global Biotechnology Industry Outlook" 10 - Tables 20 - Figures 70 - Pages The Global Biotech Industry Outlook for 2025 aims to provide insights into the anticipated performance of the biotech sectors, covering AI integration in drug discovery and the development of innovative therapies. The report will assess the industry's performance in 2024 relative to…
PR Newswire
09/01/2025

Cytosurge Announces Strategic Leadership Transition

Simon Egli Appointed Chief Executive Officer as Co-Founder Pascal Behr Transitions to Board of Directors This leadership evolution strengthens Cytosurge's commitment to integrating operational excellence and innovation, driving advancements in cell-line engineering and single-cell profiling to support both academic and commercial research.“I want to thank Pascal on behalf of the Board of Directors for his exceptional leadership and dedication over the years, and Simon for stepping into...
Nasdaq GlobeNewswire
09/01/2025

Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing…

CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investorsProceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development HORGEN, Switzerland, Jan.09, 2025(GLOBE NEWSWIRE) -- Numab Therapeutics AG(“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today...
Nasdaq GlobeNewswire
09/01/2025

Carestream's Focus HD Detectors, DRX-Rise Mobile X-ray System Receive European…

“This is an important step for Carestream,” said Jane Moverley, International Sales Director, Digital Radiology. “We're excited to be able to bring our powerful, budget-friendly DRX-Rise Mobile X-ray System to such a pivotal market, and we're even more excited to see how we can help our customers grow as their needs change.”The DRX-Rise Mobile X-ray System is a fully-integrated, feature-rich unit that can deliver improved performance, advanced productivity, and pristine image quality, as...
Nasdaq GlobeNewswire
09/01/2025

Henkel's Smartwash™ Defines a New Era of Clean at CES® 2025

"Our Smartwash concept leverages Henkel's chemical expertise, our understanding of our consumers, and our ability to innovate at pace with AI technology," says Frank Meyer, Corporate Senior Vice President and Head of R&D of Henkel Consumer Brands. "After years of internal development, now collaborating with industry partners is a pivotal moment. With Smartwash, together we will transform the laundry and dish care industry with elevated performance, more convenience, and a…
PR Newswire
09/01/2025

Ori Biotech Expands Team to Advance IRO Commercialization and Industry…

Company Making Additions to Executive Team and Advisory Board to Support Significant Commercial Momentum Oribiotech Ltd(Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announces new additions to its leadership, including the appointment of two new members to its senior team and new members to its Strategic Advisory Board (SAB). This team expansion supports the commercial launch of IRO ®, Ori's next-generation CGT manufacturing platform, and reinforces the...
Nasdaq GlobeNewswire
09/01/2025

Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology

Peter van de Sande, Head of Synaffix, said: "This latest licensing deal with MTPC highlights the appeal of our industry-leading ADC technology offering. MTPC is a key collaborator for us, expanding our presence in the APAC region, and we are excited to work alongside such a large and reputable corporation with the aim to make a tangible difference for patients in areas of high unmet medical need." Peter van de Sande, Head of Synaffix, said: "This latest licensing deal with MTPC…
PR Newswire
09/01/2025

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC…

Peter van de Sande, Head of Synaffix, said: "Boehringer Ingelheim is a leader in oncology treatment development, and the selection of our ADC technologies to further bolster their pipeline portfolio is a strong recognition of the potential of these technologies to maximize the therapeutic index of ADCs. This licensing agreement represents the culmination of a successful preclinical evaluation of our technology." Peter van de Sande, Head of Synaffix, said: "Boehringer Ingelheim is…
PR Newswire
09/01/2025

Ultimovacs ASA: Notification of major holdings

Oslo, 9 January 2025:Reference is made to the stock exchange notices published by Ultimovacs ASA (the " Company ") on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the " Business Combination ") and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the " Private Placement ") and (ii) today on 9 January 2025 regarding the approval by an extraordinary general…
Nasdaq GlobeNewswire
09/01/2025

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

Uli Brödl graduated as a Medical Doctor from Ludwig-Maximilians University Munich. He is a board-certified internist and endocrinologist and an Adjunct Professor of Internal Medicine at the Ludwig-Maximilians University Munich. Uli Brödl graduated as a Medical Doctor from Ludwig-Maximilians University Munich. He is a board-certified internist and endocrinologist and an Adjunct Professor of Internal Medicine at the Ludwig-Maximilians University Munich. "The unique focus on improving the...
PR Newswire
09/01/2025

Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies TAIPEI, Taiwan, Jan.09, 2025(GLOBE NEWSWIRE) -- Primo Biotechnology (“Primo”) today announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear medicine production. The partnership includes a supply and exclusive distribution agreement to introduce Ilumira (n.c.a. lutetium-177, Lu-177), SHINE's high-purity therapeutic...
Nasdaq GlobeNewswire
09/01/2025

KFSHRC's Study Named Among Top 10 Most Impactful Papers of 2024

RIYADH, Saudia Arabia, Jan.09, 2025(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has solidified its reputation as a global leader in medical innovation with its study on fully robotic liver transplants recognized as one of the Top 10 Most Impactful Papers of 2024 by the American Society of Transplantation. Building on KFSHRC's legacy of breakthroughs, the study, 'Outcomes of Fully Robotic Recipient Living Donor Liver Transplant about the Open...
Nasdaq GlobeNewswire
09/01/2025

Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025

Oslo, January 9, 2025:Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company's website.For further information, please seewww.ultimovacs.comor contact: Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA Email: [email protected]: +47 480 96 355 Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASAEmail: hans...
Nasdaq GlobeNewswire
09/01/2025

Philips appoints Jie Xue as Chief Business Leader Precision Diagnosis, co-leader…

January 9, 2025 Amsterdam, the Netherlands – Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips' Executive Committee and report directly to Roy Jakobs, CEO of Philips.Ms. Xue joins Philips from GE Healthcare to lead the Precision Diagnosis business...
Nasdaq GlobeNewswire
09/01/2025

Hisense ConnectLife Brings an Intelligent Experience to the Future Smart Home…

Hisense elevates smart homes with ConnectLife's new expanded functionality. Integrating with Google Home, ConnectLife controls all your smart devices, from Hisense appliances to Matter-certified thermostats, all in one app. It provides a 3D view for real-time monitoring, personalized automation, and one-touch energy saving with the AI Eco mode. ConnectLife's suite of AI features, including Dish Designer, AI Food Recognition and AI Meal Planner, simplifies meal planning, creates personalized…
PR Newswire
09/01/2025

Astraveus Announces World First End-to-End Production of CAR-T Cells Using…

The fully automated Lakhesys Benchtop Cell Factory™ integrates the entire cell therapy manufacturing process and onboard analytics into an all-in-one system, harnessing advanced microfluidic technology for optimal cell quality and efficient processing. Through scalable parallelization from pre-clinical to commercial stages, the Lakhesys™ Benchtop Cell Factory drastically reduces cost of goods, minimizes required lab space, and eliminates cell stress throughout the manufacturing process. The...
PR Newswire
09/01/2025

Alchemab Therapeutics enters into collaboration with Lilly to discover, research…

Alchemab has acquired hundreds of ALS samples, and this collaboration will leverage Alchemab's technology to identify antibodies associated with resilience in ALS patient samples and advance the most promising candidates. Alchemab has acquired hundreds of ALS samples, and this collaboration will leverage Alchemab's technology to identify antibodies associated with resilience in ALS patient samples and advance the most promising candidates. Alchemab's Chief Executive Officer,Jane Osbourn,...
PR Newswire
09/01/2025

Implantica announces new exceptional published data from the largest real-world…

Dr. Lehmann's study conclusion presented medical treatment with PPI reduced from 94.9% (before surgery) to 2.5% (after surgery) at follow-up. The study results show outstanding safety and effectiveness results demonstrating significant improvements both in PPI use and in quality of life, showing median improvements in GERD-HRQL (Gastro-Esophageal Reflux Disease - Health-Related Quality-of-Life) score of 100% and mean improvements of 92.4%. These outstanding outcomes are especially encouraging as…
PR Newswire
09/01/2025

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

COPENHAGEN, Denmark, January 9, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million asannounced on December 11, 2024. The decision to launch the program is driven by a better-than-expected performance and improved visibility pertaining to the Company's Travel Health business, with synergies from a number of recent and near-term expected events as described in the December 11 announcement.Bavarian Nordic will hold the...
Nasdaq GlobeNewswire
09/01/2025

ONWARD Medical Announces First Commercial Sales of ARC-EX System

UW Medicine and Next Steps Chicago both purchased systems in late December 2024ARC-EX is the first and only FDA approved technology indicated to improve hand strength and sensation in people with spinal cord injuryARC-EX was named a 2024 TIME Magazine Best Invention EINDHOVEN, the Netherlands, Jan.09, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function,...
Nasdaq GlobeNewswire
09/01/2025
Altri  Comunicati